Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

February 25, 2020

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 50 min

Earnings Call Speaker Segments

Jee Hamlyn-Harris

executive
#1

Thanks, operator, and I'm glad all of you could join us today as we review how Penumbra performed in the fourth quarter and wrap up 2019. On the Investors section of our site, www.penumbrainc.com, you'll find the press release together with the financial tables, and those tables include the reconciliation between GAAP and non-GAAP figures. During this call, we'll be offering forward-looking statements, which fall under the safe harbor protections granted by the Private Securities Litigation Reform Act of 1995; those statements will address things like our financial results, commercialization efforts, clinical trials, regulatory status, quality, compliance and business trends. A number of risks and uncertainties might make our actual results turn out quite differently from anything stated or suggested in those forward-looking statements. Among them are the risks described in our 10-K for the year ended December 31, 2019, which we anticipate submitting to the SEC on February 25, 2020. Given that possibility, we strongly advise you against putting excessive weight on these forward-looking statements, and we suggest you look at our periodic filings with the SEC — the 10-K I just referenced included — to get a more thorough picture of these factors and other risks that might affect our future results or the market price of our stock. Penumbra takes no responsibility to refresh or amend any forward-looking statements because of fresh information, upcoming occurrences, changes, or anything else. A number of the financial metrics discussed on this call are reported on a non-GAAP footing. You can find a reconciliation between GAAP and non-GAAP figures in the press release we have posted. The prepared remarks for today's call should take about 18 minutes. Adam Elsesser, who serves as Penumbra's Chairman and CEO, will begin with an update covering the fourth quarter and year-end, then move into a review of the business. After that, Maggie Yuan, our Chief Financial Officer, will go over the financial results for the fourth quarter and year-end; and finally, Sri Kosaraju, our President, will wrap things up with our 2020 revenue guidance and some closing remarks. At this point, I'd like to hand things over to Adam Elsesser.

Adam Elsesser

executive
#2

Thanks, Jee. Good afternoon, everyone, and I appreciate you being here for our call covering the fourth quarter and the close of 2019. Penumbra delivered a robust fourth quarter and a solid wrap-up to the year. Fourth-quarter 2019 total revenues came in at $145.3 million, which was up 20.3% as reported versus the fourth quarter of 2018. Operating income during that quarter reached $10.6 million, compared with $6.7 million in the matching period a year earlier. Looking at the financial metrics, 2019 proved to be a remarkable year. We brought in $547.4 million in total annual revenues, reflecting 23% growth relative to the prior year. Our gross profit increase was actually larger, coming in at 27.2%, and we closed out the year having produced $47.5 million in operating income. On the balance sheet side, we're in a strong position, holding over $189 million in cash with no debt whatsoever. A key point is that 2019 brought substantial progress on our goal of reaching a continually expanding global patient population; we held our first-ever Investor Day on December 3, and there we presented several core themes that have fueled our achievements and that we anticipate will remain at the heart of what we do moving forward. I'd like to take a moment to walk through 3 of those specific themes. Innovation is the first. Since 2015, we've brought more than 18 new products to market, and the engine powering our innovation grows stronger annually. That trend carried into last year with the introduction of JET 7 featuring extra flex technology. For Penumbra and for the field, this newest technology marked a major leap forward. Beyond that, we have confidence in a robust pipeline ahead and a steady cadence of new technology introductions in 2020 and afterward. The second theme concerns patient markets. We grew the number of patients we're able to help — that we could help during 2019. In our Vascular business, we secured FDA clearance for our Indigo system to treat pulmonary embolism, or PE. Once PE is included, we estimate roughly 425,000 addressable patients annually in the United States could be treated using our Indigo system. Relative to that, this amounts to more than double the addressable patient opportunity we identify in ischemic stroke. Also, last year, in our Neuro business, we broadened our global footprint. For the Penumbra System for ischemic stroke, 2019 was our first complete year of launch in China; we foresee enormous opportunities in delivering our newest cutting-edge technologies to the remaining parts of the world. The third theme we discussed involves new medical conditions, or new areas. We constantly seek to advance development in new areas. To give you one example, in the prior year we shared news that the FDA had granted clearance for the REAL system, which is aimed at neuro rehab; getting to that point took several years of work by our team at Penumbra. Then, throughout 2019, we began assembling a committed group of people to support ongoing development and the commercial rollout of the REAL system. For our company, this has been an exciting fresh endeavor; it allows us to work more closely with physicians and providers, and to bring better options to what could be millions of individuals who need after-care. That serves as a great example of how we aim to do work that matters and create future growth for our business. As we move past 2019, our business is broader and offers more paths to expansion than ever before. Combined, the opportunities we see globally add up to a total addressable market well above $10 billion, and we're eager to pursue further opportunities to grow on that foundation. As Penumbra grows, we remain intensely focused on the fundamentals we believe are critical for creating durable growth. We're cultivating a diverse, collaborative environment, attracting and retaining talented individuals while developing strong leaders from within. I want to close my remarks with several business updates and a look at our approaches for upcoming expansion; we hold conviction about where our business is headed and about our innovation pipeline, which we think is capable of speeding up our growth trajectory. Sri will cover this when he shares our revenue guidance for 2020. This year, Japan will create a headwind because of reimbursement modifications and recent talks with the partner that distributes for us. Even with that effect, we anticipate the possibility that our growth speeds up during the latter half of this year and on into 2021. Turning to our Vascular business, it keeps expanding quickly. During the fourth quarter, we recorded outstanding sequential growth from both our thrombectomy and embolization franchises. That expansion stems from our capacity to connect with additional specialist physicians, additional centers, and our capacity to increase procedure penetration. We foresee enormous opportunities across the coming several years to be present in more centers, more procedures, and to treat considerably more patients. A further key element of our vascular growth will be our capacity to innovate beyond existing technology. During 2019, we brought out no new technologies in this space; during 2020, we intend to release 2 new peripheral thrombectomy technologies, 1 midway through the year and 1 at year's end. We believe these launches are going to contribute to the strong expansion and momentum we're seeing in Vascular. Turning to Neuro, we saw decent sequential growth during Q4. It's become more difficult for us to gauge the size of the stroke thrombectomy market, given the recent unevenness in the market as well as new competitors entering. According to our latest 2019 figure, somewhere around 43,000 to 45,000 patients in the United States received treatment with mechanical thrombectomy. We believe that during 2020, the market will continue to grow by an absolute patient number that's similar. As for the most recent stroke technology we've launched, the feedback from physicians on JET 7 with XTRA FLEX technology has been very positive; never before in our company's history has a product given us this level of trackability. During our previous quarterly update, we noted that the results tied to this product are enabling certain doctors to start reducing their reliance on stentrievers. Looking forward to 2020, our Neuro growth plan will center on furthering innovation in stroke thrombectomy while expanding our offerings across the care continuum. We've said before that we anticipate bringing a new interventional stroke product to market in the United States during this year, which will keep pushing forward the way stroke procedures are performed and meet the essential need for rapid and full revascularization. We also just introduced the REAL system for neuro rehabilitation, and I'd like to spend a moment sharing some early developments. Back at our December Investor Day, we unveiled the REAL system and talked through the scientific basis, the technology behind it, the addressable market and our early commercial approach. Even though it's quite early, the first conversations with providers have left me deeply impressed. Across the past few weeks, we estimate we've held more than 200 initial customer meetings inside acute care hospitals. Nearly everyone grasps the scientific underpinnings and why our distinctive blend of immersive, full presence virtual reality within a fully mobile wireless device matters. There's substantial excitement about seeing a novel solution capable of assisting neuro patients in after-care. Our interventionless physician customers are helping unite their rehab colleagues and administration to consider how REAL might fit into their care settings and strategy. Also, only 2 weeks ago, we were at the American Physical Therapy Association, or APTA, meeting in Denver. That's the biggest conference for physical therapists across the United States. It gathered more than 15,000 professionals; we ran over 40 demo stations that stayed busy for 3 straight days, which reinforced the feedback regarding this novel technology and what it can achieve for patients. Since this is a new sales cycle, we're still figuring out how the process will play out, yet it's evident this matters and providers perceive tremendous possibilities for their patients. We plan to share additional news as the launch moves forward this year. Before I finish my remarks, I want to welcome someone valuable who has joined Penumbra's leadership: our new Chief Financial Officer, Maggie Yuen. Maggie brings more than 20 years of experience as a finance executive, and she most recently served as Vice President of Finance at Thermo Fisher Scientific's Genetic Sciences division. In this new position, Maggie will concentrate on internal finance operations priorities. Those efforts will assist us in supporting the next stage of growth and scale. She complements our team well and will collaborate closely with Sri and Lambert Shiu, our Chief Accounting Officer. We're thrilled that she's joined the Penumbra team. Maggie, we're glad to have you with us.

Maggie Yuen

executive
#3

Thanks, Adam. Speaking for myself, I'd like to pause and express my gratitude to you and Sri for the chance to be appointed and to become part of the Penumbra family. Since arriving at Penumbra just a few months ago, my excitement regarding this company and what lies ahead has only grown. During this brief period, I've participated in our inaugural Investor Day, our U.S. National Sales Meeting, and my initial year-end close here. I've had the chance to meet numerous wonderful, outstanding individuals and have developed a clearer picture of Penumbra's encouraging, teamwork-driven culture. I'm eager about the many years to come. For Q4, which concluded on December 31, 2019, total revenues reached $145.3 million — up 20.3% as reported and 20.8% on a constant currency basis versus the fourth quarter of 2018. The geographic breakdown of sales during the quarter was 66% U.S. and 34% international. Neuro accounted for 59% of sales while Vascular made up 41%. Our Vascular segment's revenue climbed to $59.8 million in Q4 2019, rising 27.9% as reported, or 28.1% in constant currency, against the comparable period a year earlier. We experienced robust sequential growth. Additionally, our year-over-year comparison reflects the launch of our peripheral embolization products in Japan during last year's fourth quarter, which we discussed previously. Revenue for our Neuro segment rose to $85.4 million in Q4 2019, a 15.4% increase as reported, or 16.1% in constant currency, versus the same period one year prior. Sales of our Penumbra system for ischemic stroke largely fueled our Neuro growth, helped by robust procedural volumes. Gross profit for the quarter came in at $98.1 million, or 67.6% of revenue, versus $78.7 million, or 65.2% of revenue, in last year's comparable quarter. Total operating expense during the quarter was $87.5 million, or 60.3% of revenue, versus $72 million, or 59.6% of revenue, a year earlier. Research and development expenses totaled $12.9 million in Q4 2019, compared with $10.9 million in Q4 2018. SG&A expenses came to $74.7 million in Q4 2019, compared with $61.2 million in Q4 2018. The rise in our spending stemmed mainly from growth in headcount and the associated compensation costs. Operating income for the quarter was $10.6 million, versus operating income of $6.7 million during the same period last year. Turning to the full year 2019, total revenues reached $547.4 million, representing a 23% increase as reported and 24.2% in constant currency versus the full year of 2018. Our Vascular segment generated $215.7 million in revenue for the full year 2019, up 43.2% as reported and 44% in constant currency. Our Neuro segment generated $331.7 million in revenue for the full year 2019, up 12.7% as reported and 14.1% in constant currency. Gross profit for the year stood at 68% of revenue, compared with 65.7% of revenue for the full year 2018. For the entire year, our operating income came in at $47.5 million, which stands against a comparable non-GAAP operating income figure of $30 million for 2018. At this point, I'd like to hand things over to Sri so he can walk through guidance and wrap up with some closing remarks.

Sridhar Kosaraju

executive
#4

Thank you, Maggie. I want to say as well how thrilled I am that you have come aboard. You strengthen what we have built in numerous respects, and the beneficial difference you are making is something we can already observe. We are now providing our outlook for revenue across the whole of 2020, spanning $635 million to $645 million — a rise of 16% to 18% compared with the prior year. Consistent with how we have done this before, this initial revenue guidance reflects our most current thinking about our markets, when new products will arrive and other pertinent circumstances; as we look at 2020, 3 notable elements shape that initial outlook. Element one concerns the anticipated release of 4 new technologies spanning Vascular and Neuro, among them the REAL system. Those 4 launches are, as things stand, projected to deliver favorable results during the second half of 2020. Element two involves Japan, tied to our recent conversations with the partner that distributes for us about present market forces in stroke as well as the opportunities awaiting us there going forward. Reimbursement adjustments affecting the Penumbra system, effective as of November, are going to weigh on today's market. For context, reimbursement covering the Penumbra system was initially put in place in Japan close to 10 years back alongside our very first stroke system. In the time since, the system has advanced, delivering improved performance while requiring fewer supporting devices, for example separators. The newly revised reimbursement amount amounts to a decrease of approximately 40% and reflects the most recent evidence on devices used in stroke cases today, where doctors have stopped relying on a separator. Element three is the shrinking demand for stent retrievers given our newest aspiration-based stroke technologies. Although our 3D revascularization device accounts for only a modest share of what we earn, we see this as a development deserving attention, and we think it may prove advantageous over the long run for our standing in the market overall. Taken together, these 3 elements point to diminished growth during the first half of 2020, then growth that speeds up in the latter half of the year, something we anticipate carrying forward into 2021. Although we generally avoid itemizing what sits behind our revenue guidance, we anticipate that the business, Japan aside, keeps expanding by more than 20% throughout 2020. To wrap up, Penumbra has achieved remarkable strides across the past several years and has laid the groundwork for the coming period of growth and impact on patients. This moment is full of promise. During our Investor Day in December, our impressive senior leaders laid out in detail the long-range growth possibilities we hold across a number of separate patient markets. And they explained why this coming period can position Penumbra as one the most selling companies in healthcare. Watching so many distinct functions inside the company rise to meet fresh obstacles that emerge as we carry out our future plan has been deeply inspiring for me. I've watched groups across development, engineering, production, marketing, sales, and support roles, every one of them putting in serious effort to get past obstacles that plenty of others were unable to clear; that comes from an amazing setting in which individuals are deeply driven and collaborate on finding solutions. That's the thing that sets Penumbra apart and the thing that will let us become an organization capable of making a real difference for millions of patients and families around the globe down the road. Thanks for being with us today, and we're grateful for your time and your interest in Penumbra. Operator, we're ready to take questions.

Jason Mills

analyst
#5

Can you hear me okay?

Adam Elsesser

executive
#6

Yes, Jason.

Jason Mills

analyst
#7

I'd like to pick up right where Sri stopped regarding the outlook, if that's alright — kind of a wide-ranging ask that may contain a few separate ones inside it. Sri, I get the idea that growth speeds up as we move through the year. As we build our models around, say, the middle point of your guidance at 17%, could you help us understand what the first half might look like compared with the second half? And inside that, how ought we to phase in the contribution, the incremental piece, coming from the REAL system as we move deeper into the year? Then I have one more thing after that.

Sridhar Kosaraju

executive
#8

Yes, Jason, I appreciate the question about guidance. This breaks into a few pieces, and let me restate a few points we made during the call, simply to make it clear. The 4 launches, clearly, in our estimation, carry impact, and a number of them will be fresh offerings with separate new revenue streams. Since they land in the back half of the year, when it comes to the whole year, those contribute very little; we won't break out, since we usually don't, the particular contributions of what those new product — revenue contributions are, especially for REAL. So if you examine it, the actual effect of Japan is essentially the delta, so to speak, in how folks view our guidance versus perhaps what we've usually put forward at the start of the year; and that's fairly simple to measure. It sits completely in Neuro and largely in stroke; during 2019, our Japanese business, as you can find in the filings, came to roughly $40 million, and as I pointed out, the reimbursement shift of approximately 40%. You can essentially run the numbers to see what that delta is; and I just want to note one thing to return to something I raised about the new product introductions. Because there isn't much in 2020, that truly means we're positioned to witness it in 2021 and growth that accelerates as we head into 2021.

Jason Mills

analyst
#9

All right. Sri, that helps. Then as a follow-up, I've got one about stroke and another about peripheral thrombectomy. Since the filing hasn't come out yet, I imagine we'll dig into it once it does; but could you discuss the market and where you stand in it for stroke during the fourth quarter? It looks like you may have seen a slight uptick in each case, both specifically and generally. Then regarding peripheral thrombectomy, Adam, I guess, specifically for pulmonary embolism with the indication, how do you intend to tackle that market, sort of ahead of your new product launch, and then what additional impact will you have there past or following that launch happening later this year.

Sridhar Kosaraju

executive
#10

Jason, perhaps I'll begin and Adam will build on the answer here. I think many people attempt to gauge where we are relative to the competitors who've already reported results for the December quarter. When you examine the figures for the fourth quarter, our Neurovascular business expanded 16.1% on a constant currency basis. I think that places us at the highest, if not the high, within the group when it comes to neurovascular results. When it comes to the stroke market, I think it's also in line with what our peers have said. As you remember, during the third quarter, we noted that the market had somewhat of a pause. We observed that continue into the start of the fourth quarter, but we saw a robust finish to the year, especially in December. We'll keep monitoring the market moving forward. I think our expectations for next year as a market are largely the same as how we entered this year, a comparable number of absolute patients; and when it comes to further on the stroke market, and our technology, perhaps I'll have Adam weigh in.

Adam Elsesser

executive
#11

Yeah, Jason — just to give you a feel for it, as you're aware, I spend a great deal of time out in the field speaking with customers. And the response to the JET 7 XTRA FLEX we have now is still remarkably strong. I mean, it truly is — like we hinted at — the finest tracking catheter we've ever offered, and the outcomes have honestly been pretty extraordinary. That said, like we've mentioned before, we aren't finished. And we believe there are ways to make it even better still. One of those products, we're confident, will arrive this year. And then we're quite enthusiastic about what we'll keep developing. So all the discussions we have regarding the other areas of our business, including our incredible Vascular business and now REAL, shouldn't suggest or subtract anything from the pride, the excitement, and the feelings we hold about how we're positioned in the stroke market. We're capable of doing both, and I believe our teams have demonstrated that. As for the other portion of your question about our pulmonary embolism, or PE, indication — I think it's honestly fairly straightforward. We're quite enthusiastic about the chance to speak openly with doctors and physicians regarding what this product can achieve in PE cases. Many of these cases involve emergent and urgent patients in genuine crisis, and I believe we've shown through the data that emerged from our trial that we can truly make an impact. The procedure time, as you know from the data, is fairly short and very compelling. And I think we'll make a significant difference for people who hadn't considered our product for that indication up to now. And that's something we're actively pursuing. That said, we haven't hinted at or explained what the new product will accomplish — or what the series of products will accomplish — but one could presume we'll make that case, or make that point, even more effectively. And without getting into any competitive advantage here, you can be sure it would be a great deal of fun to launch the new ones too.

Bob Marcus

analyst
#12

Sure. Following Analyst Day, I was curious—now that you've launched REAL VR and begun engaging with people—have you started those discussions, and what responses have you received up to now?

Adam Elsesser

executive
#13

Absolutely. Robbie, I appreciate that. It's an excellent question. I mentioned this briefly during the prepared remarks and gave a bit of quantification. In acute hospital environments, we've held more than 200 discussions; this begins with our existing neuro customers and involves them inviting their colleagues who handle rehab in those acute settings. I've been present personally in quite a few of those discussions. So the team's been at this for just over a month now, a little more than that. And honestly, the discussions have gone remarkably well. This clicks for people right away. Our doctors get it, since they recognize that after a stroke, not every patient is fully on board, and there's genuine effort still to come. Sometimes that's really tough. For some of these patients, things don't always work out smoothly. But the biggest enthusiasm is coming from the physical and occupational therapists. That's true not just in the hospital meetings I've sat in on, but also at the APTA meeting I brought up in Denver, where they tend to grasp it quite fast. They see what they're currently accomplishing, yet they get why a fully immersive, presence-driven setting matters — one where that instrument can genuinely be leveraged to, putting it casually, or in terms of phrasing, fool the mind into accomplishing what isn't possible in ordinary reality. And it's quite uncommon for someone to fail to grasp this fairly fast. So as the year progresses, we'll share increasingly more details about it. But at this early point, nothing has really come along that has dampened our excitement.

Bob Marcus

analyst
#14

Great. And perhaps only one more thing regarding that guidance topic. I missed it, though Sri, could you provide anything regarding Neuro compared with peripheral expansion? I realize you normally won't separate those figures, but perhaps simply in qualitative terms, what's the way to consider it? I believe you mentioned Japan plus the way to consider it, which perhaps hadn't been completely reflected in street models. Yet even so, the guidance range arrived below what most folks had been expecting. So whatever detail you might provide on that. Folks simply wish to feel reassured it isn't shedding share within U.S. stroke or as fresh rivals grow more visible upon the peripheral side, whatever detail you might offer so as to give added confidence regarding the underlying figures would be excellent.

Sridhar Kosaraju

executive
#15

Yes, yes. And that's a wonderful, that's a wonderful chance to sort of restate a point we included within our remarks today: that the Japan business, we keep having plenty of optimism regarding going forward. Market volumes for stroke keep expanding. Thus this — the pricing consequence from the reimbursement modification is truly experienced in 1 year during 2020. Yet we emphasized our — expansion of our business beyond Japan; and should you step back plus consider what we're discussing here, the progression of what we presented at the Investor Day along with discussing the 4 new product launches plus the capacity to contribute to growth, we stated what the guidance means is the rest of our business expand beyond 20% during 2020. Now I additionally responded within Jason's question that the timing of those launches, since they're so weighted toward the back of the year, we don't really see much of that during 2020, which, once more, indicates to you that we're positioned for speeding growth during 2021. So from an isolated standpoint of 2020, yes, Japan is burdening the growth. Yet if you consider sort of the long-term trajectory of our business plus what we set out at the Investor Day for 2023. I would say we're not just very much on track; but I think on today's call, it ought to come through that we feel even more confident in our capacity to reach there.

Bob Hopkins

analyst
#16

I'd like to revisit how we should think about the guidance for Japan, since I came away from the Analyst Day feeling that you had told us — you gave us some preview of this, noting growth of only 5% during the first 9 months. You also stated your belief that it wouldn't grow in 2020. So between the Analyst Day and now, did your learnings shift, or was the reimbursement cut bigger than you expected? Or did I simply misunderstand your comments at the Analyst Day?

Adam Elsesser

executive
#17

Bob, this is Adam. I'll do my best to respond to that. Regarding Japan, at present we view our business there as falling into 2 categories. The first consists of the products we already have in Japan. Perhaps I should begin by saying — our relationship with a distributor in Japan that has been with us a very long time is excellent. We've partnered with them for many years. Our stroke products and coils, mainly our peripheral coils, are distributed by them. Those businesses, stroke in particular, are still strong, except for this reimbursement problem. The second category — and I believe this hasn't come up before, and in our prepared remarks we note that we've had recent discussions — involves newer products not yet in Japan. With our distributor partner, we've reached agreement that our new interventional products, such as Indigo, which hasn't yet received approval in Japan, will continue to be distributed by them, while noninterventional products, such as the REAL system, will be commercialized by us directly. So there's some nuance in that. And despite the near-term challenges just described regarding reimbursement and everything else, we continue to anticipate meaningful opportunities across all our products, REAL included, in Japan over the long term.

Bob Hopkins

analyst
#18

No, that's useful context. I'm just wondering whether a few of these things came about following the Analyst Day, since I honestly thought I'd gotten the Japan message during the Analyst Day. And then — and clearly, it's — once more, it isn't a major issue or anything in the bigger picture, but I'm simply kind of wondering, was this information that sort of was already common knowledge during the Analyst Day or did it kind of take place later on.

Sridhar Kosaraju

executive
#19

Yes. The reimbursement matter was clearly widely known during the Analyst Day. And I believe we even brought it up and offered the same remarks regarding how large the reimbursement change was. So I think the calculation on that is the calculation on that in December. And what's different today, if you want to call it different, is that conversations were continuing concerning sort of the following stage of products; and I think that's what we're making clear today, and that is new. And clearly, from where we sit, it's wonderful for us and our partner in how we both view the future together.

Bob Hopkins

analyst
#20

All right. And there's one more small item I'd like to bring up very briefly regarding the 2020 guidance you provided. I appreciate what you said about the U.S. stroke market from a patient standpoint. Do you — and apologies if this was covered already, but are you assuming your market share stays essentially flat, and that you grow roughly in line with the figures you gave for new patient volumes? Or is share loss or share gain built in? I just want a sense of what's assumed there on U.S. stroke.

Sridhar Kosaraju

executive
#21

Yes. As in previous years, we haven't really given specifics on how we expect our share to move. I think we aim to offer our best assessment of the market, which honestly is becoming somewhat tougher to pin down precisely, but our confidence in that market view is solid. Another point we can make regarding share is that JET 7 XTRA FLEX has clearly been out there for some time, and the experience with it, I think, is fairly well understood. The extra technologies arriving in 2020 and afterward, I think, are another lens through which to gauge our position, so to speak; and we'll need to wait for those before offering more color; but as with what we've done in earlier years, Bob, all of those factors are reflected in the guidance, and guiding on market share isn't really something we attempt.

Bob Hopkins

analyst
#22

All right. And in the guidance you've given for this year, are you factoring in any REAL sales? Apologies — this is just one final question.

Sridhar Kosaraju

executive
#23

Yeah. So once more, I'm sorry that my answer on this isn't satisfying, since we won't break the pieces apart. To return to the point Adam made, we're clearly out having conversations with folks about it; we're picking up a great deal. For us, it's a fresh sales cycle. What I'd say — I think our description of the feedback is that it's on the better end, if not exceeding what we'd anticipated when we launched this exercise during our first few months. Describing sales at this moment is somewhat too early. Therefore, our approach to giving updates will lean a bit more toward the qualitative side, much like what we shared today. And once we move nearer to talks about revenue and to having visibility. We will definitely offer that.

Larry Biegelsen

analyst
#24

Right, I get that you're not going to discuss share from here on out. But previously, at least judging by what came out for Q4, you had said in the past that Penumbra's stroke products get used in 60% to 65% of stroke procedures. So does that remain true all the way through 2019? And then, as a second question, what are you seeing when it comes to conversion over to JET 7? Are there certain customers or clinicians who'd rather stay with the ACE68?

Sridhar Kosaraju

executive
#25

Larry, regarding the first thing you asked, about that 60% to 65% — yes, we absolutely still think we sit within that range. Let me put it as plainly as I can. Please don't take today's guidance the wrong way. Our confidence in the stroke business and in what's ahead of us is unchanged, or perhaps stronger, compared with how it stood previously; you can see that reflected in the way we describe our innovation pipeline. So our sense of what we can achieve with new technology and its capabilities is unchanged, or perhaps stronger. And to remove any doubt, the guidance has zero bearing on our view of the remaining business; this relates solely to Japan and reimbursement.

Larry Biegelsen

analyst
#26

And then switching over to…

Adam Elsesser

executive
#27

Oh, Larry, right, my apologies, Larry. On your question about converting to Jet 7, that shift is absolutely still happening. Honestly, like we've said before, it's quite sticky. Some doctors, as you're aware, this is an extremely personal decision. Different people prefer different access tools — certain ones go with long sheaths, such as our Neuron MAX product, while others choose balloon guides. That can affect which catheter they pick, depending on what works with each of those access tools. So some physicians might not convert because of that, and that's okay. We believe, as I've hinted at, that as our tools keep advancing this year and next, we'll give them strong reasons to keep rethinking their present methods in favor of increasingly modern ones. We're quite skilled at this; and our technology has been doing so for a long time, as you know, 5 years ago, we were discussing moving people from stentrievers to aspiration and that transition is well along; so we believe there's still opportunity to keep making those shifts as our products advance and, honestly, become easier to track and quicker at removing clot. So that's the aim of the case.

Larry Biegelsen

analyst
#28

Then moving to REAL. I value the context you gave before. When it comes to REAL, what are the accounts you've talked with responding to the most? Also, have you run into any initial hurdles to uptake, or adjustments you've needed to make to how the business is structured?

Adam Elsesser

executive
#29

Sure, Larry, happy to take that. That's an excellent question. The mediate — there's kind of a layer of a moment of realization I've witnessed fairly regularly, again, I've sat in quite a few of these discussions to genuinely get a sense of it. The first thing that hits basically every therapist when they come across this is pretty simple: "Wow, this thing will actually pull my patients in — the ones who usually push back against therapy. They're dealing with depression, and everything about their circumstances has shifted dramatically compared with only a handful of days earlier, before whatever event brought them here." We're talking about talks that happen in acute hospital settings, and we're able to get them involved. Getting them involved happens fast, in a manner that honestly isn't possible out in the everyday world, so to speak. That reaction is the first bit of magic. Once they begin to grasp what this system accomplishes at the level of its scientific underpinnings, that understanding tends to lock everything into place, since at that point the whole thing becomes coherent. That is the progression, or the usual response, that we have observed, and it is genuinely potent. As for the last question—whether any obstacles exist, or anything at all that has caused us to adjust our financial model or our business model—the response is no. Not so far.

Brandon Vazquez

analyst
#30

Brandon Vazquez here, filling in for Margaret. My first area of interest is the peripheral business, along with peripheral vascular. From what I remember of the Analyst Day, there are, I believe, 2 new products expected to come to market during 2020. So when you consider those upcoming products, where do you expect the biggest payoff — could they assist in bringing in new accounts, possibly unlocking fresh market opportunities, maybe allowing different sizes to be applied in new procedures, or simply boosting utilization? How are you framing those products, particularly with an eye toward 2020?

Adam Elsesser

executive
#31

That's a terrific question. I can't really disclose what those products are just yet, since, as you're aware, I have to be cautious given competitive considerations. Our perspective is essentially all of the above, so to speak. As you know, we participate in the arterial space and the venous space, plus PE. The products differ somewhat, and each will bring advantages across those distinct vascular beds; we believe the set of tools arriving at mid-year and at the end of the year will address the full scope of those applications, or get as near to that as this phase allows. And we believe we can — they're going to perform better. In our view they'll make the cases simpler, quicker, improved, everything that will keep pushing physicians toward recognizing that merely taking out the blood clot. During an acute situation beats dissolving it or macerating it and dispersing it through the remainder of the body. That's the path we believe these new products will keep helping us travel across the different vascular beds.

Brandon Vazquez

analyst
#32

Understood. Alright, that's clear to me. Moving on to a second question — sort of remaining on the peripheral side — embolization within the Vascular segment is also a fairly substantial business. And it seems to me we devote somewhat less attention to it. So perhaps you could describe, at a broad level, the size of the opportunity in that market. At medical conferences, and even during a few of your earnings calls, I believe there's been discussion of wide-ranging uses for those embolization coils. So how would you assess the scale of that market? What's your current level of penetration? And how much runway remains ahead?

Adam Elsesser

executive
#33

Sure, Brandon, good question. We have not quantified that market so far, whether by patients or by cases. But allow me to tackle it in this manner. Consider only the detachable coil market — that market is well defined. Now consider the broader space in which any device, any embolization device — pushable coils, detachable coils, liquids, glues, foams, gels — could be used. Plenty of products exist for that, including plugs. In all of those, we see an opportunity where we're able to make a difference. Think about why we've been successful: our offerings are very distinctive. Our products aren't designed to resemble what other companies sell. They are larger coils; they are gentler coils; they are coils capable of halting mid-way inside a high-flow vessel rather than traveling farther downstream; these designs are truly one of a kind. And I believe the work our remarkable engineers have invested is now bearing fruit, since these products are required in this area; and we observe that momentum building; so I doubt we can express it as a market on the same scale as the peripheral thrombectomy market, yet it is still far from trivial, and in our view there is room for further growth there.

Jee Hamlyn-Harris

executive
#34

That brings us to the end, and speaking for the management team, we appreciate you being with us today and for the interest you've shown in Penumbra. We're eager to share our next update with you — that will come during our call for the first quarter.

Operator

operator
#35

This concludes today's conference call. Thank you for joining. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.